A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Adverse Events

  Measured over: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

• Number of Participants With Serious Adverse Events

  Measured over: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

• Number of Participants With Adverse Events Leading to Discontinuation

  Measured over: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

• Number of Participants Who Died

  Measured over: From first dose to primary cutoff date (Up to approximately 43 months)

• Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

  Measured over: From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)

Changes Tremor has spotted